Skip to main content
Cidara Therapeutics Announces Formation of Scientific Advisory Board Press Releases

Cidara Therapeutics Announces Formation of Scientific Advisory Board

Comprised of World-Renowned Experts in Virology, Fungal Diseases and HematologySAN DIEGO, July 27, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced the formation of a scientific advisory board (SAB) and the appointment of four leading experts in viral and fungal infections and hematology. The SAB will work closely with the Cidara management team to…
wpengine
July 27, 2020
Cidara Therapeutics to Participate in B. Riley Virtual Summer Series Panel on Antiviral Therapeutics Press Releases

Cidara Therapeutics to Participate in B. Riley Virtual Summer Series Panel on Antiviral Therapeutics

SAN DIEGO, July 17, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the B. Riley FBR Virtual Summer Series panel on antiviral therapeutics on Tuesday, July 21, 2020. Presentation Information:Panel: Antiviral TherapeuticsDate: Tuesday, July 21, 2020Time: 1:00 PM ET / 10:00 AM…
wpengine
July 17, 2020
Cidara Therapeutics Added to Russell 3000® Index Press Releases

Cidara Therapeutics Added to Russell 3000® Index

SAN DIEGO, June 29, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been added to the Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open today, June 29, 2020. Russell indexes are widely used by investment managers and institutional investors for index…
wpengine
June 29, 2020
Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19 Press Releases

Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19

SAN DIEGO, June 23, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Cantor Fitzgerald "Winning Ways to Treat Infections and COVID-19" Virtual Symposium on Tuesday, June 30, 2020. The discussion is intended to provide important updates on how innovative companies, such…
wpengine
June 23, 2020
Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference Press Releases

Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference

SAN DIEGO, June 11, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present virtually at the Raymond James Human Health Innovations Conference on Thursday, June 18, 2020. Presentation Information:Date: Thursday, June 18, 2020Time: 3:40 PM ETWebcast: A live audio webcast and replay of the…
wpengine
June 11, 2020
Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO and CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing…
wpengine
May 20, 2020
Cidara Provides Corporate Update and Reports First Quarter 2020 Financial Results Press Releases

Cidara Provides Corporate Update and Reports First Quarter 2020 Financial Results

SAN DIEGO, May 13, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended March 31, 2020, and provided an update on its corporate activities and product pipeline. "We are pleased to report that we have recently activated our first clinical trial site for the Phase 3 ReSPECT trial,…
wpengine
May 13, 2020
Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Press Releases

Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Abstract Book highlights new data from Cidara accepted for presentation at ECCMID 2020 Phase 2 trial shows superiority of rezafungin in time to clear deadly infection Seven abstracts highlight new data on influenza antiviral conjugates (AVCs) from Cloudbreak® antiviral platform SAN DIEGO, May 05, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced the publication…
wpengine
May 5, 2020
Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group’s Infectious Disease Virtual Conference Press Releases

Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group’s Infectious Disease Virtual Conference

SAN DIEGO, April 28, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two panels discussing antifungal and COVID-19 therapies at the upcoming Infectious Disease Virtual Conference presented by Maxim Group. Presentation Information:Panel:"Antifungals"Date:Tuesday, May 5, 2020Time:12:15 - 1:45 PM ET Panel:"COVID-19 (Therapeutics)"Date:Tuesday, May 5, 2020Time:3:45 - 5:00 PM ET…
wpengine
April 28, 2020
Cidara Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference Press Releases

Cidara Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

SAN DIEGO, April 07, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020. Presentation Information:Date: Tuesday, April 14, 2020Time: 2:50 PM ETWebcast: A live audio webcast and replay of the presentation will be available in the Investors…
wpengine
April 7, 2020
Skip to content